[go: up one dir, main page]

MX2011008661A - Purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. - Google Patents

Purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.

Info

Publication number
MX2011008661A
MX2011008661A MX2011008661A MX2011008661A MX2011008661A MX 2011008661 A MX2011008661 A MX 2011008661A MX 2011008661 A MX2011008661 A MX 2011008661A MX 2011008661 A MX2011008661 A MX 2011008661A MX 2011008661 A MX2011008661 A MX 2011008661A
Authority
MX
Mexico
Prior art keywords
dimethylphenylsulfanyl
phenyl
piperazin
purification
piperazine
Prior art date
Application number
MX2011008661A
Other languages
English (en)
Inventor
Heidi Lopez De Diego
Michael Harold Rock
Vigan Nicholajsen Henrik
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2011008661A publication Critical patent/MX2011008661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a un proceso para la producción de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
MX2011008661A 2009-02-17 2010-02-16 Purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. MX2011008661A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20797209P 2009-02-17 2009-02-17
DKPA200900223 2009-02-17
PCT/DK2010/050039 WO2010094285A1 (en) 2009-02-17 2010-02-16 Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
MX2011008661A true MX2011008661A (es) 2011-09-06

Family

ID=42101395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008661A MX2011008661A (es) 2009-02-17 2010-02-16 Purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.

Country Status (27)

Country Link
US (1) US8598348B2 (es)
EP (1) EP2398785B1 (es)
JP (1) JP5738774B2 (es)
KR (1) KR101639833B1 (es)
CN (1) CN102317272B (es)
AR (1) AR075436A1 (es)
AU (1) AU2010214956B2 (es)
BR (1) BRPI1006975B1 (es)
CA (1) CA2751498C (es)
CL (1) CL2011001992A1 (es)
CO (1) CO6400224A2 (es)
DK (1) DK2398785T3 (es)
EA (1) EA020473B1 (es)
ES (1) ES2441079T3 (es)
HR (1) HRP20131236T1 (es)
IL (1) IL214178A (es)
MX (1) MX2011008661A (es)
NZ (1) NZ594658A (es)
PL (1) PL2398785T3 (es)
PT (1) PT2398785E (es)
RS (1) RS53074B (es)
SG (1) SG173735A1 (es)
SI (1) SI2398785T1 (es)
SM (1) SMT201400010B (es)
TW (1) TW201033181A (es)
WO (1) WO2010094285A1 (es)
ZA (1) ZA201105992B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2800746B1 (en) 2012-01-03 2019-04-17 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
BR112015006075B1 (pt) 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
EA028300B1 (ru) 2012-12-13 2017-10-31 Х. Лундбекк А/С Композиции, содержащие вортиоксетин и донепезил
MX362355B (es) * 2013-02-22 2019-01-14 H Lundbeck As Proceso de fabricacion de vortioxetina.
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
US10414741B2 (en) 2013-09-30 2019-09-17 Cadila Healthcare Limited Amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN103788020B (zh) * 2014-01-22 2015-11-04 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
CN105669594A (zh) * 2014-11-19 2016-06-15 康普药业股份有限公司 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法
CN105801517A (zh) * 2014-12-30 2016-07-27 上海奥博生物医药技术有限公司 一种沃替西汀氢溴酸盐新晶型及其制备方法
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN105439980B (zh) * 2015-05-08 2017-10-24 北京北陆药业股份有限公司 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法
CN105367515B (zh) * 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
CN106316985B (zh) * 2015-06-18 2021-11-09 郑州深蓝海生物医药科技有限公司 一种β型高效氢溴酸沃替西汀转晶方法
WO2017125504A1 (en) * 2016-01-20 2017-07-27 Amneal Pharmaceuticals Company Gmbh Polymorphic forms of vortioxetine hydrobromide tert-butanolate
MX2018015759A (es) 2016-07-01 2019-03-21 H Lundbeck As Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
BR112018076411A2 (pt) * 2017-04-25 2019-04-09 H. Lundbeck A/S processo para a preparação de hbr de vortioxetina na forma alfa
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN112125868B (zh) * 2020-09-25 2021-08-03 中山万远新药研发有限公司 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852974A (en) 1958-04-17 1960-11-02 Parke Davis & Co Ethers and means for producing the same
FR2186237B1 (es) 1972-05-03 1975-10-31 Synthelabo
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
AU2007260355B2 (en) * 2006-06-16 2013-08-15 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

Also Published As

Publication number Publication date
HK1165955A1 (en) 2012-10-12
SI2398785T1 (sl) 2014-01-31
KR20110126625A (ko) 2011-11-23
EA020473B1 (ru) 2014-11-28
PT2398785E (pt) 2013-12-26
CN102317272A (zh) 2012-01-11
KR101639833B1 (ko) 2016-07-14
PL2398785T3 (pl) 2014-07-31
CA2751498C (en) 2017-09-12
SG173735A1 (en) 2011-09-29
AR075436A1 (es) 2011-03-30
BRPI1006975A2 (pt) 2020-08-18
JP5738774B2 (ja) 2015-06-24
EA201171065A1 (ru) 2012-02-28
CO6400224A2 (es) 2012-03-15
IL214178A (en) 2014-09-30
NZ594658A (en) 2013-02-22
TW201033181A (en) 2010-09-16
AU2010214956B2 (en) 2012-08-23
DK2398785T3 (da) 2013-12-16
US20120004409A1 (en) 2012-01-05
WO2010094285A1 (en) 2010-08-26
JP2012517961A (ja) 2012-08-09
CN102317272B (zh) 2014-11-12
ES2441079T3 (es) 2014-01-31
SMT201400010B (it) 2014-03-07
US8598348B2 (en) 2013-12-03
AU2010214956A1 (en) 2011-09-22
CL2011001992A1 (es) 2012-04-09
ZA201105992B (en) 2012-10-31
CA2751498A1 (en) 2010-08-26
BRPI1006975B1 (pt) 2022-11-22
EP2398785A1 (en) 2011-12-28
EP2398785B1 (en) 2013-11-27
IL214178A0 (en) 2011-08-31
RS53074B (sr) 2014-04-30
HRP20131236T1 (hr) 2014-02-14

Similar Documents

Publication Publication Date Title
MX2011008661A (es) Purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
CL2014001765A1 (es) Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
TN2011000504A1 (en) Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl) phenyl] piperazine
SA113340696B1 (ar) تصنيع 2-(5-برومو-4-(4-سيكلو بروبيل نافثالين-1-يل)-4 h-1، 2، 4- ترازول-3- يل ثيو) حمض أسيتيك
PL2981520T3 (pl) Nowy sposób syntezy 1-(2-((2,4-dimetylofenylo)tio)fenylo)piperazyny
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
ZA201201360B (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
NI200900153A (es) Nuevo procedimiento de síntesis de la agomelatina.
MX360703B (es) Proceso mejorado para la elaboración de 5-(2, 6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amin a.
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
NI200900152A (es) Nuevo procedimiento de síntesis de la agomelatina
IN2012DN01971A (es)
RU2009124318A (ru) Средство для предупреждения и коррекции двигательных, экстрапирамидных нарушений, вызванных нейролептиками
CY1115048T1 (el) Καθαρισμος 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης
EP2226325A4 (en) PROCESS FOR THE PRODUCTION OF 4- (PHENYL-SUBSTITUTED) HEXAHYDROPYRIDOÝ2,1-CÝÝ1,4¨OXAZIN-6-ONE
UA35653U (en) 2-(4-aryliden-2,5-dioxyimidazolidine-1-yl)-n-arylazetamides having antileukemic activity
MX2009012727A (es) Procedimiento para preparar pentahidroxihexilcar-bamoilundecanoato de bencilo.
ME03428B (me) Postupak za proizvodnju 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted